Fuhong Hanlin (02696.HK): The application for a phase 1 clinical trial of HLX05-N, a biosimilar of cetuximab injection, for the treatment of metastatic colorectal cancer (mCRC) has been approved by the US FDA.

Widely Finance APP News, Fosun Pharma (02696.HK) announced that recently, the company's independently developed bevacizumab injection biosimilar HLX05-N (recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection) (HLX05-N) for the treatment of metastatic colorectal cancer (mCRC) has received approval for an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA). The company plans to conduct a relevant Phase 1 clinical trial in the United States once conditions are met.